Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 153 for:    covid-19 convalescent plasma
Previous Study | Return to List | Next Study

Efficacy and Safety of COVID-19 Convalescent Plasma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04397523
Recruitment Status : Completed
First Posted : May 21, 2020
Last Update Posted : May 11, 2021
Sponsor:
Collaborator:
University Clinic for Infectious Diseases, North Macedonia
Information provided by (Responsible Party):
Institute for Transfusion Medicine of RNM

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Completed
Actual Primary Completion Date : May 10, 2021
Actual Study Completion Date : May 10, 2021
Publications:
Huaxia, (2020). 'China puts 245 COVID-19 patients on convalescent plasma therapy', Xinhua.net, 2 February. Available at: http://www.xinhuanet.com/english/2020-02/28/c_138828177.htm
https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-deviceexemption-ide-process-cber/investigational-covid-19-convalescent-plasma-emergency-inds Accessed on March 30,2020
Guidance on collection, testing, processing, storage, distribution and monitored use. An EU programme of COVID-19 convalescent plasma collection and transfusion. EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY, 08 April, 2020
AABB's CCP Collection Protocol - Donor Eligibility, Processing, Labeling and Distribution, 03 April, 2020 http://www.aabb.org/advocacy/regulatorygovernment/Documents/COVID-19-Convalescent-Plasma-Collection.pdf